An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis

Gastroenterology

Volumn 134, Issue 4, 2008, Pages 1137-1147

  Baggio, Laurie L ^a,b,c   Huang, Qingling ^a,b,c   Cao, Xiemin ^a,b,c   Drucker, Daniel J ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HUMAN SERUM ALBUMIN; HUMAN SERUM ALBUMIN EXENDIN 4; PROTEIN C FOS; RECOMBINANT PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONJUGATION; CONTROLLED STUDY; DRUG MECHANISM; ENERGY YIELD; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH EMPTYING; WEIGHT REDUCTION;

EID: 41349098117     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.01.017     Document Type: Article

References (36)

1. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
2. Drucker D.J. The biology of incretin hormones. Cell Metab 3 (2006) 153-165
3. Xu G., Stoffers D.A., Habener J.F., et al. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
4. Stoffers D.A., Kieffer T.J., Hussain M.A., et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes 49 (2000) 741-748
5. Li Y., Hansotia T., Yusta B., et al. Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem 278 (2003) 471-478
6. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
7. Eng J., Kleinman W.A., Singh L., et al. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem 267 (1992) 7402-7405
8. Young A.A., Gedulin B.R., Bhavsar S., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48 (1999) 1026-1034
9. Kolterman O.G., Buse J.B., Fineman M.S., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 3082-3089
10. Agerso H., Jensen L.B., Elbrond B., et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45 (2002) 195-202
11. Wang M, Kipnes MS, Matheson S, et al. Safety and pharmacodynamics of CJC-1134-PC, a novel GLP-1 receptor agonist, in patients with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blind, dose-escalation study (Poster 498). Propanel Abstracts of the 67th Scientific Sessions of the American Diabetes Association, June 22-26, 2007, Chicago, IL, p A133.
12. Scrocchi L.A., Brown T.J., MacLusky N., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 2 (1996) 1254-1258
13. Hansotia T., Maida A., Flock G., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117 (2007) 143-152
14. Asakawa A., Inui A., Yuzuriha H., et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124 (2003) 1325-1336
15. Elias C.F., Kelly J.F., Lee C.E., et al. Chemical characterization of leptin-activated neurons in the rat brain. J Comp Neurol 423 (2000) 261-281
16. Yamamoto H., Kishi T., Lee C.E., et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23 (2003) 2939-2946
17. Yamamoto H., Lee C.E., Marcus J.N., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110 (2002) 43-52
18. Franklin K., and Paxinos G. The mouse brain in sterotaxic coordinates (1997), Academic Press, Burlington, MA
19. Folch J., Lees M., and Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226 (1957) 497-509
20. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 25 (2001) 402-408
21. Imeryuz N., Yegen B.C., Bozkurt A., et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273 (1997) G920-G927
22. Nagell C.F., Wettergren A., Orskov C., et al. Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41 (2006) 667-672
23. Baggio L.L., Huang Q., Brown T.J., et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004) 2492-2500
24. Zander M., Madsbad S., Madsen J.L., et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
25. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
26. Wang Y.H., Egan J.M., Raygada M., et al. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 136 (1995) 4910-4917
27. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17 (2003) 161-171
28. Elbrond B., Jakobsen G., Larsen S., et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25 (2002) 1398-1404
29. Kinzig K.P., D'Alessio D.A., and Seeley R.J. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22 (2002) 10470-10476
30. Hellstrom P.M., and Naslund E. Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiol Behav 74 (2001) 735-741
31. Chuang V.T., Kragh-Hansen U., and Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19 (2002) 569-577
32. Abbott C.R., Monteiro M., Small C.J., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (2005) 127-131
33. Talsania T., Anini Y., Siu S., et al. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
34. Andrikopoulos S., Massa C.M., Aston-Mourney K., et al. Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high-fat diet. J Endocrinol 187 (2005) 45-53
35. Hull R.L., Andrikopoulos S., Verchere C.B., et al. Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52 (2003) 372-379
36. Jhala U.S., Canettieri G., Screaton R.A., et al. cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2. Genes Dev 17 (2003) 1575-1580